Cited 14 times in
A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.date.accessioned | 2015-06-10T13:01:43Z | - |
dc.date.available | 2015-06-10T13:01:43Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/110876 | - |
dc.description.abstract | BACKGROUND: The standard chemotherapy regimen for advanced gastric cancer has not yet been established. We investigated the efficacy and the safety of the combination of docetaxel with infusional 5-fluorouracil (5-FU) and leucovorin (FLT) in advanced gastric cancer. METHODS: Patients received docetaxel 75 mg/m(2) (1-hour infusion) followed by a leucovorin bolus 20 mg/m(2) and a 24-hour infusion of 5-FU 1,000 mg/m(2) (day 1-3) every 3 weeks. The response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the toxicity was evaluated by National Cancer Institute common toxicity criteria (NCI-CTC). RESULTS: Sixty-six patients were enrolled. Median relative dose intensity was 86%. Of 57 evaluable patients, the overall response rate was 25.7%. The response rate was 34.2% in chemonaïve patients and 14.2% in the patients who had previously received treatment. Median time to progression and overall survival duration were 5.2 and 9.7 months, respectively. The most frequent grade 3-4 toxicity was neutropenia, which was the major cause of treatment delay. Other hematological and nonhematological toxicities were rare. CONCLUSIONS: The FLT regimen showed a comparable efficacy with other second-generation regimens. Because of the low nonhematological toxicity, this could be a potential alternative to the cisplatin-containing regimens in gastric cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 63~70 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/secondary | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Antineoplastic Agents, Phytogenic/administration & dosage | - |
dc.subject.MESH | Docetaxel | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intravenous | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Taxoids/administration & dosage | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Jeung H.-C. | - |
dc.contributor.googleauthor | Rha S.Y. | - |
dc.contributor.googleauthor | Kim Y.T. | - |
dc.contributor.googleauthor | Noh S.H. | - |
dc.contributor.googleauthor | Roh J.K. | - |
dc.contributor.googleauthor | Chung H.C. | - |
dc.identifier.doi | 10.1159/000091186 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03794 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 16446551 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/91186 | - |
dc.subject.keyword | Docetaxel | - |
dc.subject.keyword | 5-Fluorouracil | - |
dc.subject.keyword | Leucovorin | - |
dc.subject.keyword | Gastric cancer | - |
dc.contributor.alternativeName | Noh, Sung Hoon | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Noh, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 70 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 63 | - |
dc.citation.endPage | 70 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.70(1) : 63-70, 2006 | - |
dc.identifier.rimsid | 54924 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.